Waldencast plc

Waldencast plc (WALD) Market Cap

Waldencast plc has a market capitalization of $193.9M.

Price: $1.64

▼ -0.08 (-4.65%)

Market Cap: 193.91M

NASDAQ ¡ time unavailable

CEO: Michel Brousset

Sector: Technology

Industry: Software - Application

IPO Date: 2021-05-12

Website: http://www.waldencast.com

Waldencast plc (WALD) - Company Information

Market Cap: 193.91M|Sector: Technology

Company Profile

Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.

Analyst Sentiment

73%
Strong Buy

From 5 Active Polls

1Y Forecast: $2.50

▲ +52.4% Potential Upside

Consensus Target Metrics

Low Bound

$2

Median

$3

High Bound

$3

Average

$3

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$2.50
▲ +52.44% Upside
Low Target
$2.00
22% Risk
Median Target
$2.50
52% Mid
High Target
$3.00
83% Max
Consensus
Buy
2 / 4 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ4 2025Q2 2025Q4 2024Q2 2024Q4 2023Q2 2023Q1 2023Q4 2022
Period EndingTrailing 12MDec 31, 2025Jun 30, 2025Dec 31, 2024Jun 30, 2024Dec 31, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Market Cap ($M)1942222764573701,336835—976
Enterprise Value ($M)3113394586245391,4911,046—1,167
Price to Earnings Ratio (P/E)-0.84-0.92-0.41-3.53-9.18-4.27-17.73—-2.28
Price/Earnings-to-Growth Ratio (PEG)—————————
Price to Sales Ratio (P/S)0.711.592.083.212.8112.277.64—10.86
Price to Book Ratio (P/B)0.420.480.550.690.602.141.36—1.53
Price to Free Cash Flow Ratio (P/FCF)-11.94-103.32-19.55400.60-29.21-96.36-47.69—-22.31
Enterprise Value to Sales (EV/Sales)—2.433.464.394.0913.709.57—12.98
Enterprise Value to EBITDA (EV/EBITDA)-2.04-294.85-3.02-555.15311.45-80.65-44.07—-10.98
Debt to Equity Ratio-0.770.320.390.270.300.280.37—0.31
⚠️

Valuation Model Suspended

API Payload Error: Inverted or negative baseline Free Cash Flow margin detected (-11.5%).

Troubleshooting Notice: The upstream financial data supplier has uploaded corrupted or inverted baseline metrics for WALD. The server sandbox cannot calculate an intrinsic value path from negative cash generation baselines.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 WALDENCAST PLC CLASS A (WALD) — Investment Overview

🧩 Business Model Overview

Waldencast PLC Class A operates as a manufacturer of engineered metal components using casting-based processes, typically supplying production programs to industrial end markets. The value chain centers on (1) design and engineering support that translates customer specifications into manufacturable casting solutions, (2) production of components through foundry and value-added operations (such as machining/finishing where applicable), and (3) delivery under quality and performance requirements that are validated through customer qualification.

Customer stickiness tends to build through qualification cycles and the operational integration required to meet specifications for safety-critical and high-reliability parts. Once a component is qualified and production is under way, substitution usually demands a requalification process, new tooling/patterns, and operational changeover—creating structural inertia in customer buying behavior.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by unit sales of manufactured components tied to customer production volumes and program schedules. Where Waldencast participates in recurring supply programs, monetisation becomes more stable than pure spot trading, reflecting long qualification lead times and ongoing orders from OEMs and Tier suppliers.

Margin drivers typically include (1) operating leverage from manufacturing utilization, (2) material sourcing discipline (cast metals and consumables), (3) mix of higher value-added operations (e.g., machining/finishing), and (4) yield and scrap reduction—critical in casting-intensive manufacturing. Cost control and throughput consistency are often the key levers that determine earnings power across the cycle.

🧠 Competitive Advantages & Market Positioning

The most durable moat in casting-based component businesses generally comes from high switching costs and process/quality intangible assets:

  • Switching Costs (Qualification & Rework Risk): Components often require formal validation, dimensional checks, metallurgy verification, and performance demonstrations. Switching suppliers can introduce schedule risk and potential quality/reliability exposure.
  • Engineering Know-How: Translating designs into successful cast outcomes depends on experience with gating/rigging, heat treatment practices, defect mitigation, and tolerancing—capabilities that are difficult to replicate quickly.
  • Operational Reliability: Consistent yield, defect rates, and delivery performance reduce customer cost of quality and line stoppage risk, supporting continued program awards.

Competitive benchmarking: Waldencast’s practical peer set for engineered cast components often includes industrial casting and engineered-parts specialists such as:

  • Precision Castparts (PCC) (aerospace-focused engineered components)
  • Howmet Aerospace (engineered metal components)
  • Nemak (aluminum components/casting-intensive manufacturing)

While these companies may differ by end-market mix and scale, they compete on a similar set of economics: qualification barriers, quality systems, manufacturing yield, and engineering integration. Waldencast’s positioning versus larger rivals typically depends on program-specific competitiveness—winning and retaining qualified supply relationships where performance, responsiveness, and manufacturing capability matter as much as size.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is usually supported by three structural themes:

  • Ongoing demand for engineered components in industrial and mobility end markets: Many engineered parts remain casting-based due to materials properties and cost-effective production of complex geometries.
  • Program wins driven by engineering execution: In industrial manufacturing, expansion often happens through incremental share gains on qualified programs, including new variants, additional SKU content, or new platform awards after successful validation.
  • Value-added mix and process improvement: Sustainable earnings growth can come from higher value-added steps (where applicable), improved yield, reduced scrap, and better throughput—translating operational excellence into margin resilience even when volumes fluctuate.

TAM expansion in this context is less about “new technology categories” and more about securing and extending qualified manufacturing content within existing industrial platforms across cycles.

⚠ Risk Factors to Monitor

  • End-market cyclicality: Demand for industrial and mobility-linked components can fall during equipment downturns and production pauses.
  • Input cost volatility: Metals and consumables can impact margins if pass-through mechanisms are delayed or incomplete.
  • Capital intensity and execution risk: Maintaining quality and capacity (and supporting customer requirements) can require steady capex and disciplined project execution.
  • Quality and warranty exposure: Casting defects, process deviations, or heat treatment variability can drive cost-of-quality and reputational damage.
  • Process disruption: Additive manufacturing and alternative forming routes may be competitive in limited areas; broad displacement is less likely for all applications, but selective substitution remains a risk.

📊 Valuation & Market View

The market typically values engineered manufacturing and component suppliers based on cash-generation durability rather than growth alone. Common valuation frameworks focus on EV/EBITDA and EV-to-free-cash-flow, with key underwriting variables including:

  • Margin stability: Yield, scrap, and operational reliability reduce earnings volatility.
  • Capital discipline: Maintenance capex needs and the ability to convert earnings into free cash flow.
  • Quality and customer retention: Evidence of program stickiness supports more stable multiple realization.
  • Volume/price dynamics: How quickly pricing or cost recovery mechanisms respond to input changes.

In this segment, the investment case is typically strengthened when the company demonstrates consistent process control, measured working-capital management, and continued wins/renewals that sustain qualified production content.

🔍 Investment Takeaway

WALDENCAST PLC CLASS A is best understood as a casting-based engineered component supplier where the central investment thesis rests on switching costs from customer qualification and operational/engineering execution. The longer-term opportunity is tied to securing and extending qualified supply relationships, improving manufacturing efficiency and yield, and maintaining margin resilience through cyclical end-market conditions.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for WALD.

globenewswire.com•2026-06-01

Waldencast Announces Sale of Obagi Medical to Bridgepoint

LONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million, marking a significant step in Waldencast's strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.

globenewswire.com•2026-05-15

Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting

Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success

globenewswire.com•2026-05-14

Obagi and Next Health Partner to Launch “The Skin Recharge Station” Pop-Up Experience

A multi-city pop-up introducing consumers to the future of skincare and longevity innovation A multi-city pop-up introducing consumers to the future of skincare and longevity innovation

globenewswire.com•2026-04-30

Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*

Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 delivers advanced mineral protection with skincare benefits for daily defense Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 delivers advanced mineral protection with skincare benefits for daily defense

globenewswire.com•2026-04-28

Waldencast announces conclusion of SEC investigation

LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, announced today that it was notified by the staff of the U.S. Securities and Exchange Commission (the “SEC”) that they have concluded their investigation of the Company relating to Waldencast's restatement of its financial results and material weaknesses in its internal control over financial reporting related to historical accounting practices used by Obagi Cosmeceuticals (the “Investigation”) and, based on the information available as of the date of the notice, the SEC does not intend to recommend an enforcement action against Waldencast.

defenseworld.net•2026-03-27

Waldencast PLC (NASDAQ:WALD) Short Interest Up 61.6% in March

Waldencast PLC (NASDAQ: WALD - Get Free Report) saw a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,205,249 shares, an increase of 61.6% from the February 26th total of 745,941 shares. Currently, 0.9% of the shares of the company are sold short. Based on

globenewswire.com•2026-03-24

Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin's Age and Restore Visible Youthfulness

The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin

globenewswire.com•2026-03-19

Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™

ProMD's multi-location physician led network will participate in Obagi's ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states ProMD's multi-location physician led network will participate in Obagi's ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states

defenseworld.net•2026-03-16

Brokerages Set Waldencast PLC (NASDAQ:WALD) Price Target at $4.42

Shares of Waldencast PLC (NASDAQ: WALD - Get Free Report) have received an average rating of "Moderate Buy" from the six research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to

globenewswire.com•2026-03-13

Waldencast Reports Q4 2025 and FY 2025 Financial Results

FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing of its credit facility. As a result, the Company enters 2026 with a strong foundation for successful growth LONDON, March 13, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended December 31, 2025 (“Q4 2025”) and year ended December 31, 2025 (“Year Ended 2025”) on Form 6-K to the U.S. Securities and Exchange Commission (the “SEC”), which are also available on our investor relations site at http://ir.waldencast.com/.

globenewswire.com•2026-03-11

Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date

LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review.

globenewswire.com•2026-02-27

Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its extensive national network of practices Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its extensive national network of practices

globenewswire.com•2026-02-25

Obagi Medical and It's a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

It's a Secret Med Spa selected as a premier luxury med spa partner due to its commitment to excellence, personalized luxury aesthetic experiences, and outstanding patient results across its growing network of high-end locations It's a Secret Med Spa selected as a premier luxury med spa partner due to its commitment to excellence, personalized luxury aesthetic experiences, and outstanding patient results across its growing network of high-end locations

globenewswire.com•2026-02-17

Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic practices nationwide Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic practices nationwide

defenseworld.net•2026-02-16

Waldencast PLC (NASDAQ:WALD) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Waldencast PLC (NASDAQ: WALD - Get Free Report) have received an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"WALD reported revenue of $139.8M in December 2025, with a net loss of $60.3M and an EPS of -$0.51. The company's total assets stand at $816.2M against liabilities of $316.1M, resulting in total equity of $500.1M. WALD operates at a negative cash flow, with operating cash flow at -$1.3M and free cash flow at -$2.15M, while not paying any dividends. The stock is currently valued at $1.13, with a significant decline of 64.13% over the past year. The price target consensus is at $2.5. The company is facing challenges in profitability and cash flow management, reflected in its negative earnings and high net losses. Despite its substantial asset base, the continuous losses may concern investors about future cash flows and potential returns. A careful examination of growth strategies and financial management practices will be crucial for recovery."

Revenue Growth

Neutral

Revenue growth is moderate but overshadowed by net losses.

Profitability

Neutral

Negative net income and EPS indicate significant profitability challenges.

Cash Flow Quality

Neutral

Negative operating and free cash flow raise concerns.

Leverage & Balance Sheet

Neutral

Strong equity position relative to liabilities provides some stability.

Shareholder Returns

Neutral

No dividends and significant stock price decline reflect poor returns.

Analyst Sentiment & Valuation

Caution

Analysts view the stock as undervalued, but concerns about performance remain.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

So What? WALD reported solid gross margin and EBITDA quality, but the quarter’s story is constrained by execution: Obagi’s Q1 supply-chain restructuring caused out-of-stocks in 3–4 key items (hurting fulfillment/growth), while Milk also faced stockouts when Hydro Grip demand beat forecasts. Management’s tone is confident on acceleration (mid-teens revenue growth and mid–high teens EBITDA margin), and they stress product availability improvement by end of Q2 after moving to a one-step/online-integrated warehousing flow. Tariff risk is framed as manageable: guidance assumes low single-digit COGS impact for all of 2025 and mitigation via supply-chain flow changes, potential low single-digit selective pricing, and supplier efficiency work; China exposure is ~10% of COGS. In the Q&A, analyst pressure focused on operational reliability, physician-channel demand drivers, and price strategy; mgmt largely attributed issues to timing/distribution mechanics and the transitional nature of restructuring—not demand collapse—yet the concrete out-of-stock disclosures make near-term delivery the key swing factor.

AI IconGrowth Catalysts

  • Milk Makeup: Hydro Grip Gel Skin Tint launched in March; sold out quickly due to demand > sales forecast
  • Milk Makeup: Ulta Beauty launch (sales beginning late February); US retail sales growth described as high single-digit
  • Obagi Medical: Out-of-stock issues expected to improve as supply chain transformation completes; mgmt expects stronger inventory by end of Q2
  • Obagi Medical: Lapped transition to first-party model with primary e-commerce distributor
  • Obagi Medical: Updated obagi.com elements drove +30% homepage conversion (Q1 YoY), plus +61% YoY earned media value

Business Development

  • Milk Makeup partnership with Nike (Nike Dark Tour in Los Angeles; started at Milk Studios in March; continues through Race weekend in June)
  • Milk Makeup expanded distribution into Ulta Beauty (initially 600 doors; evaluating expansion within Ulta/at Target based on early results)
  • Ulta and Sephora cited as key retail/digital touchpoints for sell-in vs sell-out dynamics

AI IconFinancial Highlights

  • Net revenue: $65.4M, down 4.1% YoY
  • Adjusted gross margin: 76.4%, up 10 bps YoY
  • Adjusted EBITDA: $4.4M, 6.7% margin
  • Milk Makeup: revenue down 15.1% YoY; adjusted gross margin 69.5% = +460 bps sequentially from Q4, but -180 bps YoY
  • Milk Makeup: adjusted EBITDA margin 14.9% of net revenue
  • Obagi Medical: net revenue $36.2M, up 7.1% YoY; adjusted gross margin up 60 bps to 82%
  • Obagi Medical: adjusted EBITDA $5.9M, 16.3% margin (higher marketing investment + higher supply chain costs)
  • Key Q&A operational hurdle: Obagi out-of-stocks in 3–4 key items due to restructuring/supply chain disruption; Milk also experienced stockouts tied to Hydro Grip demand
  • Tariffs: mgmt assumes tariffs remain for all of 2025; expects low single-digit % increase in fiscal 2025 COGS, already reflected in guidance
  • Mitigation (tariffs): optimize supply chain flows to reduce China exposure; prepare selective pricing likely low single-digit range; deepen supplier collaboration for efficiencies

AI IconCapital Funding

  • Cash: $10.8M at quarter end
  • Revolver availability: additional $22.5M on new revolving credit facility
  • Net debt: $172.1M vs $154.2M at end of 2024 (increase tied to refinancing cost; maturity profile extended to March 2030)
  • Share count: 123M shares outstanding as of April 30, 2025
  • No buyback amount disclosed in transcript

AI IconStrategy & Ops

  • Supply chain transformation: consolidating third-party logistics providers and optimizing distribution center network (Obagi)
  • Operational change described in Q&A: streamlined flow from two-step warehousing to one-step; integrated with online warehousing (caused some Q1 disruption moving inventory between locations)
  • Mgmt goal for flexibility: improve lead times/inflexibility to respond to demand peaks driven by marketing and selling activities

AI IconMarket Outlook

  • Full-year guidance: net revenue growth in the mid-teens
  • Full-year guidance: adjusted EBITDA margin in the mid to high-teens
  • Tariff assumption: no further material change to current tariffs
  • Operational expectation: improved product availability by end of Q2

AI IconRisks & Headwinds

  • Obagi: restructuring supply chain disruptions leading to lower fulfillment rates and out-of-stocks on key products (explicitly cited as 3–4 key items); this dampened growth
  • Milk: stockouts as Hydro Grip Skin Tint demand exceeded expectations (inventory not available to fully meet sell-through early)
  • Macro/retail: decelerating beauty market and fluid macro/retail environment; pressure from softer consumer sentiment and spending
  • Physician channel: mgmt did not cite a broad physician-demand slowdown; slowdown attributed to loss of Amazon tailwinds from prior-year distributor conversion transition
  • Sell-in vs sell-out pressures (Milk): EU pressure (retail partners transitioning inventory); U.S. digital channel anniversarying last year’s Jelly’s launch drove complexity in sell-through dynamics
  • Tariffs/cost: China exposure limited to ~10% of total COGS; mgmt indicated worst-case China tariff back to 145% would still be not material; potential selective pricing only if needed

Sentiment: MIXED

Note: This summary was synthesized by AI from the WALD Q1 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for WALD.

SEC EDGAR Live Feed
No recent 10-K available.
No recent 10-Q available.
Loading financial data and tables...
📁

SEC Filings (WALD)

© 2026 Stock Market Info — Waldencast plc (WALD) Financial Profile